Each week we highlight five things affecting the life sciences industry. Here’s the latest.
- The America First investment policy could introduce uncertainty in the thriving U.S.-China biotech sector, hindering cross-border collaborations.
- While disruptions to biotech licensing deals are unlikely, the policy may affect future investments and partnerships between U.S. and Chinese biotech firms, according to Fierce Pharma.
- A U.S. federal judge has issued a nationwide injunction preventing the administration from implementing significant reductions to National Institutes of Health research grants.
- Fierce Biotech reports that the proposed cuts aimed to cap indirect cost reimbursements at 15%, potentially saving the government $4 billion annually, but faced legal challenges from 22 states and numerous research institutions.
- The Wall Street Journal reports that Merck is facing a patent dispute with a biotech company over an enzyme used in a new injectable version of its top-selling oncology drug, Keytruda. Merck claims it developed the enzyme independently, while the counterparty argues that the new Keytruda infringes on its patents and requires a licensing agreement.
- With Keytruda’s U.S. patent expiring in 2028, Merck aims to shift from the current intravenous version to an injectable option to maintain market dominance and counter competition from generics.
- European biopharma manufacturers are increasingly considering nearshoring—relocating production closer to home—to enhance supply chain resilience and reduce dependency on distant markets.
- This shift is driven by factors such as supply chain disruptions, geopolitical tensions and the desire for greater control over manufacturing processes, reports Pharmaceutical Technology.
- Forbes reports that effective data governance is crucial for pharmaceutical companies to harness artificial intelligence’s potential, ensuring data quality, compliance and ethical standards.
- Implementing robust data strategies enhances AI-driven drug development, leading to more efficient and accurate outcomes.
For more insights in life sciences, check out RSM’s industry outlook.